Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Lanadelumab (Takhzyro®) is a safe and effective prophylactic drug for use in patients with hereditary angioedema, researchers reported in a study published in the World Allergy Organizational Journal.
Hereditary angioedema with C1 inhibitor deficiency is characterized by recurring, painful edema attacks involving subcutaneous or submucosal tissue, primarily driven by the overproduction of bradykinin. The disease burden is considerable, owing to its highly unpredictable nature, which can limit activities of daily living.
The treatment for hereditary angioedema is 2-fold: on-demand treatment and prophylaxis. One of the drugs currently recommended for long-term prophylaxis is lanadelumab. It is used in patients with type 1 and 2 hereditary angioedema with C1 inhibitor deficiency who are aged at least 12 years. Studies have indicated it is a safe and effective prophylactic agent.
Researchers conducted a single-center study comparing extended and standard dosing regimens of lanadelumab. Nine patients with hereditary angioedema were recruited for this study.
Read more about hereditary angioedema treatments
The mean number of edema attacks among these patients was 5.9 per month, and all attacks were abdominal or cutaneous in nature. The patients were randomized into 2 groups: standard treatment (lanadelumab every 2 weeks) and extended treatment (lanadelumab every 4 weeks).
After 36 weeks of treatment, the authors of the study reported that all patients experienced significant improvements in the number of attacks per month. Five of the 9 patients achieved complete remission from attacks. All patients reported a significant improvement in their quality of life. No adverse effects were reported.
“Based on our findings, lanadelumab is an effective prophylactic medication in difficult-to-treat [hereditary angioedema] patients,” the authors of the study concluded. “It remains unclear whether, in routine clinical practice, there is significant benefit in using a 300 mg two-week regimen versus a 300 mg four-week regimen.”
Reference
Abuzakouk M, Ghorab O, Al-Hameli H, Salvo F, Grandon D, Maurer M. Using an extended treatment regimen of lanadelumab in the prophylaxis of hereditary angioedema: a single-centre experience. World Allergy Organ J. 2022;15(7):100664. doi:10.1016/j.waojou.2022.100664
